≤10% BCR-ABL at 3 months may impact OS1
In a retrospective trial, BCR-ABL transcript levels were analyzed in 282 patients with chronic phase CML who were monitored at 3, 6, and 12 months to identify molecular milestones that predicted for OS and other outcomes.1
The hazard of disease progression was 91% lower for patients in the group that received 3 to 4 RQ-PCR tests per year compared with the group that received 0 RQ-PCR tests per year.2
*Limitations Apply. Non-US residents, patients covered under Medicare, Medicaid, or a similar state or federal program, and residents of Massachusetts and Michigan are not eligible for the Get IS RQ-PCR Now program. Novartis reserves the right to rescind, revoke, or amend the program without notice.
OS, overall survival; IS, International Scale; CML, chronic myeloid leukemia; RQ-PCR, real-time quantitative polymerase chain reaction.
References: 1. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232-238. 2. Goldberg SL, Chen L, Guerin A, et al. Curr Med Res Opin. 2013;29(9):1075-1082.